08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

Immunovative, Immunovative Therapies deal

Immunovative Inc. (formerly Novo Energies Corp. ) said it received notice from Immunovative Therapies to immediately terminate a December 2011 license deal granting Immunovative Inc. exclusive, worldwide rights to commercialize products covered by Immunovative Therapies'...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Clinical News

AlloStim: Phase I/II data

Immunovative Therapies Ltd. , Shoham, Israel   Product: AlloStim   Business: Cancer   Molecular target: NA   Description: IV formulation of activated CD4+ T cells   Indication: Treat refractory solid tumors   Endpoint: Safety; anti-tumor...
08:00 , Jan 23, 2012 |  BC Week In Review  |  Company News

Immunovative Therapies, Novo Energies deal

In December, Immunovative granted Novo Energies an exclusive, worldwide license to commercialize all products covered under Immunovative's patents or patent applications. Immunovative, which has rights to the IP from the University of Arizona , will...